Long-term problems in younger low-risk COVID-19 patients; flu shot may
offer some protection
Send a link to a friend
[October 20, 2020]
By Nancy Lapid
(Reuters) - The following is a roundup of
some of the latest scientific studies on the novel coronavirus and
efforts to find treatments and vaccines for COVID-19, the illness caused
by the virus.
Long-term health problems seen in low-risk COVID-19 patients
Young, healthy adults with COVID-19 who do not require hospitalization
are still at risk for long-term health problems, Oxford University
researchers found. They studied 201 recovering UK patients with an
average age of 44, more than 90% of whom did not have risk factors such
as diabetes, high blood pressure, or heart disease. Only 18% had been
sick enough to be hospitalized. At an average of 140 days after their
symptoms began, 98% were still fatigued, 92% had heart and lung
symptoms, 88% had muscle aches, 87% had breathlessness, 83% headaches,
and 73% gastrointestinal symptoms. Organ damage was more common among
those who had been hospitalized. But it was not limited to that group as
66% of the patients had impairment of at least one organ. Magnetic
resonance imaging (MRI) scans showed mild damage to lungs in 33%, heart
in 32%, pancreas in 17%, kidneys in 12%, liver in 10% and spleen in 6%.
The researchers say their study, posted on Friday on medRxiv ahead of
peer review, cannot prove the virus caused these later issues. But it
does suggest long-term monitoring of organ function will be necessary
even in relatively low-risk patients.
Flu shot may help protect against COVID-19
Flu vaccines may help the body defend itself against COVID-19, according
to a Dutch study that found hospital workers who got a flu shot last
winter were less likely to become infected with the new coronavirus. In
test tube experiments, the researchers saw that last winter's flu
vaccine could prime healthy cells to respond more effectively not just
to the flu, but also to the new coronavirus. When they analyzed COVID-19
rates among staff at their hospital, they found the number of infections
was 39% lower among those who had gotten a flu vaccine. "These data,
combined with similar recent independent reports, argue for a possible
beneficial effect of influenza vaccination against both influenza and
COVID-19," the researchers say. "This could mean that the flu vaccine
could offer partial protection against both infections this winter."
They posted their report on medRxiv on Friday ahead of peer review. "We
thought it was important to publish these results already because the
flu shot is made available to a large group of people," study leader
Mihai Netea of Radboud University Medical Center said in a news release.
Pandemic increases need for strength training by elderly
[to top of second column]
|
A 3D-printed coronavirus model is seen in front of a world map and
the words "CoronaVirus Disease (Covid-19)" on display in this
illustration taken March 25, 2020. REUTERS/Dado Ruvic
Older people "urgently" need to be doing resistance exercises, also
known as strength training, during the pandemic, to counteract the
effects of physical inactivity and to make sure they retain at least
the same level of muscle function they had prior to lockdowns and
stay-at-home orders, doctors advise. Social distancing measures
cause "greater time at home and consequently a reduction in general
physical activity and an increase in sedentary time, which is
harmful to older people," they write in the medical journal
Experimental Gerontology. Home-based resistance training can be done
with exercises that simulate daily physical activities and can be
adapted to each person's physical condition. Earlier studies showed
that "even minimally supervised home-based resistance training can
be a safe, effective and low-cost exercise option to increase lower
body muscle strength in older individuals with a variety of health
conditions," the researchers say. The U.S. Centers for Disease
Control and Prevention offers a pamphlet on strength training for
older adults, available here: (https://bit.ly/2FKS5FO). The agency
urges anyone with any medical condition discuss the exercises with
their physician before starting. (https://bit.ly/3kcXpAB)
Hydroxychloroquine fails to protect medical workers
The malaria drug hydroxychloroquine failed to protect healthcare
workers caring for COVID-19 patients from becoming infected
themselves, according to results of a formal, placebo-controlled
trial published on Saturday in Clinical Infectious Diseases. The
1,483 participants worked in emergency departments, intensive care
units, and other high-risk sites in the United States and the
Canadian province of Manitoba. They were randomly assigned to
receive hydroxychloroquine 400mg, once weekly or twice weekly, for
12 weeks, or a placebo. Compared to the risk of infection in the
placebo group, the risk was 28% lower with once-weekly
hydroxychloroquine and 26% lower with twice-weekly dosing. But those
differences were not deemed to be statistically significant, meaning
they could have been due to chance rather than to the drug. The
University of Minnesota researchers point out that recruiting
participants became difficult after potential adverse heart effects
of the drug were publicized, and also that the hydroxychloroquine
doses may have been too low. "Investigation into more frequent
dosing may be warranted," they said.
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |